Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Riboflavin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.69 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.69 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.92 |
| ▸ | USP2 | O75604 | 4/20 | 0.92 |
| ▸ | HAT1 | O14929 | 4/20 | 0.92 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.92 |
| ▸ | HTT | P42858 | 4/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.92 |
| ▸ | RECQL | P46063 | 3/20 | 0.92 |
| ▸ | CASP7 | P55210 | 3/20 | 0.92 |
| ▸ | MAPT | P10636 | 3/20 | 0.92 |
| ▸ | CASP1 | P29466 | 2/20 | 0.92 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.92 |
| ▸ | TST | Q16762 | 2/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | HBB | P68871 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL2798981 | 1.00 | MEN1 (0.92) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL7135127 | 1.00 | MEN1 (0.92) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL2127865 | 1.00 | MEN1 (0.92) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL23824874 | 0.96 | MEN1 (0.92) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL13373926 | 0.96 | MEN1 (1.00) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL12979917 | 0.96 | MEN1 (1.00) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL2420598 | 0.96 | MEN1 (1.00) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL7706 | 0.96 | MEN1 (1.00) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL14146654 | 0.96 | MEN1 (1.00) | MEN1KMT2AUSP2HAT1RBBP7 | |
| Riboflavin SCHEMBL7707 | 0.96 | MEN1 (1.00) | MEN1KMT2AUSP2HAT1RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-4637775-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS Therapeutics LLC (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2025131038-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025079090-A1 | SUBSTITUTED 4-HETEROATOM-ISOQUINOLONE COMPOUNDS, PROCESS OF PREPARATION AND APPLICATIONS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2025-04-17 | — | — | WO | claimed |
| CN-119504471-A | Aryl amino acid derivative of targeting large neutral amino acid transporter 1 and preparation method and application thereof | 四川大学华西医院 | 2025-02-25 | — | — | CN | claimed |
| CN-119431194-A | The method comprises the following steps of18Preparation method of F-DOPA and F-18 labeled precursor thereof | 四川大学华西医院 | 2025-02-14 | — | — | CN | claimed |
| CN-119390516-A | Preparation method18Method for preparing F-m-fluorobenzylguanidine | 四川大学华西医院 | 2025-02-07 | — | — | CN | claimed |
| CN-119350192-A | Phenoxyalkyl guanidine derivative of targeting norepinephrine transporter as well as preparation method and application thereof | 四川大学华西医院 | 2025-01-24 | — | — | CN | claimed |
| CN-119185313-A | Leishmod prodrug, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-12-27 | — | — | CN | claimed |
| CN-119118880-A | F-18 marked PSMA inhibitor and preparation method and application thereof | 四川大学华西医院 | 2024-12-13 | — | — | CN | claimed |
| CN-118771310-A | No-drying18F-Solution, preparation method and application thereof | 四川大学华西医院 | 2024-10-15 | — | — | CN | claimed |
| WO-2024137921-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2024-06-27 | — | — | WO | claimed |
| CN-117509877-A | Method for preprocessing pharmaceutical wastewater based on nitrate synergistic riboflavin tetraacetate | 合肥工业大学 | 2024-02-06 | — | — | CN | claimed |
| CN-117326973-A | Method for preparing asymmetric Schiff base containing aryl by high-efficiency photocatalytic oxidation of benzylamine derivative | 大连理工大学 | 2024-01-02 | — | — | CN | claimed |
| CN-113582873-A | Method for preparing N-benzyl enamine by efficiently photo-catalytically oxidizing benzylamine | 大连理工大学 | 2021-11-02 | — | — | CN | claimed |
| WO-1993010784-A1 | THERAPEUTIC COMPOSITION AND METHOD FOR PREVENTING REPERFUSION INJURY | UNIVERSITY OF MICHIGAN (US) | 1993-06-10 | — | — | WO | claimed |
| US-5153236-A | Comprising an N-aryl-alpha-amino acid and a photosensitizer such as a thixoanthone, isoalloxazine or coumarine; high sensitivity to UV and visible light; storage stability; photoresists; relief images | HITACHI CHEMICAL CO., LTD. (JP) | 1992-10-06 | — | — | US | claimed |
| JP-60243007-A | — | — | None | — | — | JP | disclosed |
| US-5153236-A | Comprising an N-aryl-alpha-amino acid and a photosensitizer such as a thixoanthone, isoalloxazine or coumarine; high sensitivity to UV and visible light; storage stability; photoresists; relief images | HITACHI CHEMICAL CO., LTD. (JP) | 1992-10-06 | — | — | US | disclosed |
| JP-S60243007-A | CAKELIKE MAKEUP COSMETIC | KANEBO LTD | 1985-12-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | STRA6, RBP4, F12 | ESR1 2450/4885ADRB2 2064/4885AGTR1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.